Anti-oxidation mesoporous organic silicon self-assembly nano material as well as preparation method and application thereof
By preparing antioxidant mesoporous organosilicon self-assembled nanomaterials, and utilizing mesoporous organosilicon spheres and a Ca2+ coating coated with curcumin, ROS can be eliminated, thus solving the problem of joint damage caused by ROS in RA and achieving stronger anti-inflammatory efficacy and lower systemic toxicity.
Patent Information
- Application Number
- CN202610176812.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-02-06
- Publication Date
- 2026-05-15
AI Technical Summary
Current RA treatments primarily work by suppressing inflammatory cells and pro-inflammatory factors, but they are unable to effectively prevent the disease from worsening. There is a lack of specific therapies for clearing reactive oxygen species (ROS), which leads to increased joint damage and disease progression.
Antioxidant mesoporous organosilicon self-assembled nanomaterials were prepared and mass-produced using a room temperature and pressure method. The mesoporous organosilicon spheres and curcumin-coated Ca2+ spheres were used to achieve ROS scavenging, exhibiting targeting and stimulus-responsive capabilities.
It achieves stronger anti-inflammatory effects, reduces systemic toxic side effects, has better biocompatibility in vivo, and can effectively relieve the symptoms of rheumatoid arthritis.
Smart Images

Figure CN122031399A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of nanomaterials and biomedical technology, specifically relating to an antioxidant mesoporous organosilicon self-assembled nanomaterial, its preparation method, and its application. Background Technology
[0002] Rheumatoid arthritis (RA) is a systemic, invasive autoimmune disease widely distributed worldwide, with a significantly higher incidence in women than men. Throughout the course of RA, over 80% of patients do not achieve effective symptom remission. The main characteristic of RA is persistent, progressive synovial hyperplasia and joint inflammation in the symmetrical small joints of the distal extremities. Most patients initially experience joint swelling, pain, and stiffness, while later stages lead to limited joint function and disability. Furthermore, the continuous progression of RA can affect multiple systems or organs, causing serious complications such as interstitial lung disease, myocardial infarction, and endocarditis, severely impacting patients' quality of life, reducing survival time, and placing a significant burden on families and society.
[0003] Currently, the main clinical treatment for rheumatoid arthritis (RA) is to inhibit the proliferation of inflammatory cells and the production of pro-inflammatory factors in the early and middle stages of RA, achieving short-term rapid analgesia and relief of clinical symptoms to maintain the patient's quality of life. This approach mainly relies on drug therapy, including nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids (GCs), disease-modifying anti-rheumatic drugs (DMARDs), and biologics. Although these drugs can relieve joint swelling and pain in RA patients, they cannot effectively prevent the disease from worsening and can only be used as adjunctive and symptomatic treatment.
[0004] The aforementioned treatment strategies focus on blocking inflammatory pathways, lacking specific therapies for clearing reactive oxygen species (ROS). ROS, a key driver of rheumatoid arthritis (RA), not only directly damages the synovium and cartilage, exacerbating local oxidative stress, but also amplifies the cycle of bone destruction and pain by activating inflammatory signaling pathways and regulating osteoclast and osteoblast differentiation. Therefore, developing a treatment method that can clear ROS to treat inflammatory diseases, especially RA, is of great significance. Summary of the Invention
[0005] The purpose of this invention is to provide an antioxidant mesoporous organosilicon self-assembled nanomaterial, its preparation method and application. The method is simple, operates at room temperature and pressure, is low in cost, and can be mass-produced. The prepared nanomaterial can be used to prepare drugs for the treatment of inflammatory diseases, especially inflammatory bone diseases, by scavenging ROS.
[0006] To achieve the above objectives, the technical solution adopted by this invention is: a method for preparing antioxidant mesoporous organosilicon self-assembled nanomaterials, comprising the following steps: S1. Preparation of TK-NH2; S1-1. Weigh mercaptoethylamine hydrochloride and add it to the reaction flask, then add concentrated hydrochloric acid and stir at room temperature until the solid is completely dissolved to obtain solution A with a concentration of 1.3~1.5 g / mL; S1-2. Prepare solution B by mixing acetone and dichloromethane at a volume ratio of (2-4):1. S1-3. Transfer the solution A prepared in step S1-1 to a low-temperature water bath. While stirring, add the solution B prepared in step S1-2 to solution A. A white solid substance will appear in the reaction flask. Continue the reaction under low-temperature conditions in the water bath for 2-4 hours. The volume ratio between solution A and solution B is 1:(3-4). After the reaction in S1-4 is completed, methanol is added to the reaction solution in S1-3. Then, the product is recrystallized with dichloromethane and filtered. The solid substance is then dissolved in methanol. When the product is just dissolved, anhydrous diethyl ether is gradually added until no more white precipitate is formed. S1-5. The reaction product obtained in step S1-4 is filtered and then dissolved in NaOH solution and stirred at room temperature. The solution after reaction is extracted with dichloromethane, anhydrous sodium sulfate is added and stirred, and then anhydrous sodium sulfate is removed by filtration. The liquid obtained by filtration is evaporated to dryness to obtain the target product. The target product is then transferred to a sample bottle and dried overnight by an oil pump to obtain liquid ROS scavenging small molecule precursor TK-NH2. S2. Preparation of antioxidant mesoporous organosilicon spheres, abbreviated as PMOs; S2-1. Prepare an anhydrous and oxygen-free reaction flask. At room temperature, disperse the TK-NH2 and triethylamine prepared in step S1 in a reaction flask containing tetrahydrofuran. The volume ratio of TK-NH2, triethylamine and tetrahydrofuran is 1:(5-6):(50-60). S2-2, 3-isocyanopropyltrimethoxysilane is added dropwise to tetrahydrofuran and mixed to obtain solution C. The volume ratio of 3-isocyanopropyltrimethoxysilane to tetrahydrofuran is 1:(1-1.5). Solution C is added to the reaction flask in step S2-1 and reacted at room temperature for 10-16 h. After evaporation, the intermediate product TK-Si2 is obtained. S2-3. Disperse triethanolamine and hexadecyl p-toluenesulfonate in water and reflux with stirring to obtain solution D; in solution D, the concentrations of triethanolamine and hexadecyl p-toluenesulfonate are 2.7~3.2 g / L and 19~20 g / L, respectively; S2-4. Mix the intermediate product TK-Si2 obtained in step S2-2 with TEOS to obtain solution E; the concentration of intermediate product TK-Si2 in solution E is 0.8~8.2 g / mL; and add solution E dropwise to solution D obtained in step S2-3 while stirring; the volume ratio between solution E and solution D is 1:(9-38). S2-5. The product obtained in step S2-4 is centrifuged and washed, dispersed in HCl-methanol solution and refluxed, and then centrifuged and washed with anhydrous ethanol to obtain PMOs, which are then stored in anhydrous ethanol. S3. Preparation of antioxidant mesoporous organosilicon self-assembled nanomaterials, abbreviated as PMOs@Cur@Ca; S3-1. Take the anhydrous ethanol solution containing PMOs prepared in step S2, centrifuge and discard the supernatant, add curcumin-ethanol solution, the concentration of PMOs in the curcumin-ethanol solution is 5-5.5 g / L; sonicate. S3-2. Then, add 1-4M CaCl2 solution to the solution obtained in step S3-1, sonicate, and incubate overnight in a shaker at 100-120 rpm and 36-37℃; the volume ratio between CaCl2 solution and curcumin-ethanol solution is (10-11):1; centrifuge and discard the supernatant, wash with ethanol solution and freeze dry to obtain PMOs@Cur@Ca nanomaterials.
[0007] Preferably, in step S2-2, the volume of solution C accounts for 15-20% of the reaction solution in the reaction flask in step S2-1; in step S2-3, the reflux temperature is 80-90℃ and the stirring time is 1-1.5h.
[0008] Preferably, in step S2-4, the stirring temperature is 80-90℃, the stirring speed is 800-1200r, and the stirring time is 12-16h; in step S2-5, the concentration of the HCl-methanol solution is 1.5-2M; the reflux temperature is 75-80℃, and the reflux time is 12-16h.
[0009] Preferably, in step S3-1, the concentration of curcumin-ethanol solution is 3.8-4.0 mg / mL; and the mixture is sonicated for 10-20 min.
[0010] Preferably, in step S3-2, the ultrasonic treatment is performed for 15-20 minutes; the centrifugation parameters are: centrifugal force of 15000-17000g, centrifugation time of 3-5 minutes; and the concentration of the ethanol solution is 10-11%.
[0011] Preferably, in steps S1-3, solution B is added to solution A at a dropping rate of 10-15 mL / min; the water bath temperature is -5℃ to 5℃; and in steps S1-4, the volume ratio between methanol and dichloromethane is 1:(1-2).
[0012] Preferably, in steps S1-5, the mass fraction of the NaOH solution is 22-27%; stirring at room temperature for 4-6 hours; extraction with dichloromethane 3-6 times; and stirring with anhydrous sodium sulfate for 10-12 minutes.
[0013] To achieve the above-mentioned objectives, this invention also provides an antioxidant mesoporous organosilicon self-assembled nanomaterial prepared by the above method, wherein the core of the self-assembled structure is a mesoporous organosilicon sphere and the core is coated with a spherical structure; the coating contains Ca. 2+ And curcumin.
[0014] To achieve the above-mentioned objectives, this invention also provides the application of the antioxidant mesoporous organosilicon self-assembled nanomaterials prepared by the above method in the preparation of drugs for treating inflammatory bone diseases.
[0015] Preferably, the inflammatory bone disease is rheumatoid arthritis.
[0016] The working principle of this invention is as follows: This invention employs a special TK-Si2 intercalation into organosilica spheres, carefully selecting the amount of TK-Si2 added to satisfy the sphere morphology while imparting excellent ROS scavenging ability. Simultaneously, the calcium coating can detach in the slightly acidic environment of inflammation, improving the targeting of the spheres. PBS containing 5mM H2O2 and 5wt% Tween 80 is used as the release medium, and samples are taken at different time points to determine the drug release amount. Figure 13 As shown, the antioxidant nano-assemblies have excellent stimulus response capabilities and can target inflammatory lesions.
[0017] Compared with the prior art, the present invention has the following beneficial effects: The method of this invention is simple, operates at room temperature and pressure, is low in cost, and can be mass-produced. The prepared antioxidant nano-assemblies can be used to prepare drugs for treating inflammatory diseases, especially inflammatory bone diseases, by scavenging ROS. In animal models of rheumatoid arthritis, single free curcumin or blank PMOs carriers can only alleviate RA-related symptoms to a limited extent, while the PMOs@Cur@Ca composite nanomaterials prepared in this invention achieve stronger anti-inflammatory efficacy, while possessing better in vivo biocompatibility and lower systemic toxicity, and are expected to be applied in the clinical treatment of inflammatory diseases such as rheumatoid arthritis. Attached Figure Description
[0018] Figure 1The TK-Si2 structure and NMR spectrum of this invention; Figure 2 This is a transmission electron microscope (TEM) image of the PMOs silicon spheres prepared in step S2 of Embodiment 1 of the present invention. Figure 3 This is a transmission electron microscope (TEM) image of silicon spheres containing PMOs@Cur@Ca prepared according to Example 1 of the present invention. Figure 4 This is a transmission electron microscope (TEM) image of the PMOs silicon spheres prepared in step S2 of Embodiment 2 of the present invention. Figure 5 This is a transmission electron microscope (TEM) image of silicon spheres containing PMOs@Cur@Ca prepared in Example 2 of this invention. Figure 6 This is a transmission electron microscope (TEM) image of the PMOs silicon spheres prepared in step S2 of embodiment three of the present invention. Figure 7 This is a transmission electron microscope (TEM) image of silicon spheres containing PMOs@Cur@Ca prepared in Example 3 of this invention. Figure 8 This is a transmission electron microscope (TEM) image of silicon spheres containing PMOs@Cur@Ca prepared in Example 4 of this invention. Figure 9 This is a transmission electron microscope (TEM) image of silicon spheres containing PMOs@Cur@Ca prepared in Example 5 of this invention. Figure 10 These are transmission electron microscopy images of the ROS response of the PMOs prepared in step S2 of Examples 1, 2, and 3 of this invention. Figure 11 The BET of the PMOs silicon spheres prepared in step S2 of embodiment one of the present invention; Figure 12 The mapping spectrum of PMOs@Cur@Ca prepared in Example 1 of this invention; Figure 13 The drug release of PMOs@Cur@Ca prepared in Example 1 of this invention; Figure 14 Photographs showing the swelling changes in the left hind paw of CIA rats after treatment with PMOs@Cur@Ca prepared using the present invention; Figure 15 Inflammation index score of CIA rats after treatment with PMOs@Cur@Ca prepared using the present invention; Figure 16 The hemolytic rate of rats at different concentrations of the drug of this invention; Figure 17 HE sections of the internal organs of rats in each group after treatment according to this invention; Figure 18 This is a schematic diagram illustrating the principle of the preparation method of the present invention. Detailed Implementation
[0019] The present invention will be further described in detail below with reference to the embodiments.
[0020] The reagents used in the following examples are listed below: Mercaptoethylamine hydrochloride: Manufacturer: Adamas Reagent Co., Ltd., Brand No. 26799B, 100g; Concentrated hydrochloric acid: Manufacturer: Xilong Scientific Co., Ltd., Brand: 22060012, 500mL; Acetone: Manufacturer: Shanghai Lingfeng Chemical Reagent Co., Ltd., Brand No.: 20220726, 500mL; Dichloromethane: Manufacturer: Shanghai Lingfeng Chemical Reagent Co., Ltd., Brand: D102507-t5L, 5L; Sodium hydroxide: Manufacturer: Shanghai Titan Technology Co., Ltd., Grade: G19852A, 500g; Anhydrous sodium sulfate: Manufacturer: Shanghai Titan Technology Co., Ltd., Grade: G82667D, 1kg; 3-Isocyanopropyltrimethoxysilane (ICPTMS): Manufacturer: Adamas Reagent Co., Ltd., Brand No. 26270C, 100g; Tetrahydrofuran (THF): Manufacturer: Adamas Reagents Ltd., Brand No. 14018AD, 500mL; Triethylamine (TEA): Manufacturer: Adamas Reagent Co., Ltd., Brand No. 17471I, 100mL; Tetraethyl orthosilicate (TEOS): Manufacturer: Adamas Reagent Co., Ltd., Grade: 83251B, 100g; Triethanolamine (TEA): Manufacturer: Shanghai Titan Technology Co., Ltd., Brand: G11366A, 500mL; Hexadecyl p-toluenesulfonate ammonium (CTAT): Manufacturer: Shanghai Aladdin Biochemical Technology Co., Ltd., Brand: 138-32-9, 50g; Curcumin: Manufacturer: Shanghai Aladdin Biochemical Technology Co., Ltd., Brand: K2420506, 5g; Calcium chloride (CaCl2): Manufacturer: Shanghai Titan Technology Co., Ltd., Grade: G10299C, 1kg; Anhydrous methanol: manufactured by Shanghai Lingfeng Chemical Reagent Co., Ltd., grade 20250717, 500mL; Anhydrous ethanol: Manufacturer: Shanghai Lingfeng Chemical Reagent Co., Ltd., Brand: E101501-s500mL, 500mL.
[0021] Example 1 like Figure 18 As shown, a method for preparing antioxidant mesoporous organosilicon self-assembled nanomaterials includes the following steps: S1. Preparation of TK-NH2; S1-1. Take a 100mL eggplant bottle, weigh 11.36g of mercaptoethylamine hydrochloride and add it to the eggplant bottle, then add 8mL of concentrated hydrochloric acid, and stir at room temperature until the solid is completely dissolved to obtain a solution A with a concentration of 1.42g / mL; S1-2, Prepare solution B by mixing 15.6g (20mL) of acetone with 8mL of dichloromethane; S1-3. Transfer the solution A prepared in step S1-1 to a low-temperature water bath at 0°C. While stirring, add the solution B prepared in step S1-2 to solution A at a dropping rate of 10 mL / min. A white solid substance appears in the reaction flask. Continue the reaction at 0°C for 2 hours. After the reaction in S1-4 is completed, methanol is added to the reaction solution in S1-3. Then, the product is recrystallized with dichloromethane and filtered. The volume ratio of methanol to dichloromethane is 1:1. The solid substance is then dissolved in methanol. When the product is just dissolved, anhydrous diethyl ether is gradually added. The addition is stopped when no more white precipitate is formed. S1-5. The reaction product obtained in step S1-4 is filtered and then dissolved in a 25% NaOH solution. The solution is stirred at room temperature for 4 hours. The solution after the reaction is extracted with dichloromethane 5 times, and anhydrous sodium sulfate is added and stirred for 10 minutes. Then, anhydrous sodium sulfate is removed by filtration. The liquid obtained by filtration is evaporated to dryness to obtain the target product. The target product is then transferred to a sample bottle and dried overnight with an oil pump to obtain the liquid ROS scavenging small molecule precursor TK-NH2. S2. Preparation of antioxidant mesoporous organosilicone spheres (PMOs); S2-1. Prepare an anhydrous and oxygen-free round-bottom flask. At room temperature, disperse 0.51 mL of TK-NH2 and 2.850 mL of triethylamine prepared in step S1 in a round-bottom flask containing 28.5 mL of tetrahydrofuran. S2-2, 2.295 mL of 3-isocyanopropyltrimethoxysilane was added dropwise to 3 mL of tetrahydrofuran and mixed well to obtain solution C. 1.56 mL of solution C was added to the round-bottom flask from step S2-1, and the mixture was reacted at room temperature for 12 h. The mixture was then evaporated to dryness to obtain the intermediate product TK-Si2. Its structural formula and NMR spectrum are shown below. Figure 1 As shown, from Figure 1 As can be seen from this, the molecular formula of TK-Si2 is C 21 H 48 N4O8S2Si2 has a molecular weight of 604.93.
[0022] S2-3. Disperse 19.65 μL of TEA (triethanolamine) and 152 mg of CTAT in 7.917 mL of water, and reflux at 80 °C for 1 h to obtain solution D; S2-4. Mix 1.73 g of the intermediate product TK-Si2 (2.86 mmol) obtained in step S2-2 with 0.2125 mL of TEOS (0.953 mmol) to obtain a solution E with a TK-Si2 concentration of 8 g / mL; and add solution E dropwise to solution D obtained in step S2-3 and stir at 80 °C and 1000 rpm for 15 h; the molar ratio between TK-Si2 and TEOS is 3:1; S2-5. The product obtained in step S2-4 is centrifuged and washed, dispersed in 30 mL of 2 M HCl-methanol solution, refluxed at 75 °C for 16 h, and then centrifuged and washed three times with anhydrous ethanol to obtain PMOs, which are then stored in anhydrous ethanol. S3. Preparation of antioxidant mesoporous organosilicon self-assembled nanomaterials, abbreviated as PMOs@Cur@Ca; S3-1. Take the anhydrous ethanol solution containing 5 mg PMOs prepared in step S2, centrifuge and discard the supernatant, add 1 mL of 4 mg / mL curcumin-ethanol solution; sonicate for 10 min. S3-2. Then, add 10 mL of 1 M CaCl2 solution to the solution obtained in step S3-1, sonicate for 20 min, and incubate overnight in a shaker at 100 rpm and 37 °C. Centrifuge at 15000 g for 3 min, discard the supernatant, wash three times with 10-11% ethanol solution, and freeze dry to obtain PMOs@Cur@Ca nanomaterials.
[0023] The morphology of the PMOs prepared in step S2 and the PMOs@Cur@Ca prepared in step S3 of this embodiment was observed using transmission electron microscopy. The results are as follows: Figure 2 and Figure 3 As shown, their shapes are uniform, such as Figure 11 As shown, the particle size range of PMOs is approximately 80-120 nm; elemental analysis of PMOs@Cur@Ca using mapping yields the following results. Figure 12 As shown, all elements are distributed, and Ca is coated on the surface of the silicon sphere.
[0024] Example 2 A method for preparing antioxidant mesoporous organosilicon self-assembled nanomaterials includes the following steps: S1. Preparation of TK-NH2; This step is consistent with Example 1; S2. Preparation of antioxidant mesoporous organosilicone spheres (PMOs); S2-1 and S2-2 remain consistent with Example 1; S2-3. Disperse 29.5 μL of TEA (triethanolamine) and 228 mg of CTAT in 11.875 mL of water, and reflux at 80 °C for 1 h to obtain solution D; S2-4. Mix 3.46 g of intermediate product TK-Si2 (5.72 mmol) obtained in step S2-2 with 1.275 mL of TEOS (5.716 mmol) to obtain a solution E with a TK-Si2 concentration of 2.7 g / mL; and add solution E dropwise to solution D obtained in step S2-3 and stir at 80 °C and 1000 r for 15 h; the molar ratio between TK-Si2 and TEOS is 1:1; S2-5 remains consistent with Example 1; S3. Prepare antioxidant mesoporous organosilicon self-assembled nanomaterials, abbreviated as PMOs@Cur@Ca; this step is consistent with Example 1.
[0025] The morphology of the PMOs prepared in step S2 and the PMOs@Cur@Ca prepared in step S3 of this embodiment was observed using transmission electron microscopy. The results are as follows: Figure 4 and Figure 5 As shown, their shapes are uniform.
[0026] Example 3 A method for preparing antioxidant mesoporous organosilicon self-assembled nanomaterials includes the following steps: S1. Preparation of TK-NH2; This step is consistent with Example 1; S2. Preparation of antioxidant mesoporous organosilicone spheres (PMOs); S2-1 and S2-2 remain consistent with Example 1; S2-3. Disperse 62 μL of TEA (triethanolamine) and 480 mg of CTAT in 25 mL of water, and reflux at 80 °C for 1 h to obtain solution D; S2-4. Mix 1.81 g of the intermediate product TK-Si2 (2.992 mmol) obtained in step S2-2 with 2 mL of TEOS (8.967 mmol) to obtain a solution E with a TK-Si2 concentration of 0.9 g / mL; and add solution E dropwise to solution D obtained in step S2-3 and stir at 80 °C and 1000 r for 15 h; the molar ratio between TK-Si2 and TEOS is 1:3; S2-5 remains consistent with Example 1; S3. Prepare mesoporous organosilicon self-assembled nanomaterials, abbreviated as PMOs@Cur@Ca; this step is consistent with Example 1.
[0027] The morphology of the PMOs and PMOs@Cur@Ca silicon spheres prepared in step S3 of this embodiment was observed using transmission electron microscopy. The results are as follows: Figure 6 and Figure 7 As shown, their shapes are uniform.
[0028] As shown in Examples 1, 2, and 3, the prepared antioxidant mesoporous organosilicone spheres (PMOs) of equal mass but different TK-Si2 contents were incubated in a 5% H2O2 system. Samples were taken at different time points, and the morphology of the silicon spheres at different time points was observed using transmission electron microscopy. The ROS scavenging ability of antioxidant mesoporous organosilicone spheres with different TK-Si2 contents was compared. Finally, it was determined that the antioxidant mesoporous silicon spheres with the TK-Si2 content in Example 3 had better ROS scavenging ability and relatively uniform morphology. Figure 10 As shown.
[0029] Therefore, the present invention selects a TK-Si2 solution with a concentration of 0.9 g / mL as the optimal content for the preparation of antioxidant PMOs, which can greatly improve the ROS scavenging ability while maintaining the basic morphology of silicon spheres, and has a good effect on subsequent ROS scavenging.
[0030] Example 4 The only difference between this embodiment and Embodiment 3 is that a 2M CaCl2 solution is used in step S3-2; all other steps and parameters remain the same as in Embodiment 3.
[0031] The morphology of the PMOs@Cur@Ca prepared in this embodiment was observed using transmission electron microscopy, and the results are as follows: Figure 8 As shown, its morphology is uniform and its surface is covered with a Ca coating.
[0032] Example 5 The only difference between this embodiment and Embodiment 3 is that a 4M CaCl2 solution is used in step S3-2; all other steps and parameters remain the same as in Embodiment 3.
[0033] The morphology of the PMOs@Cur@Ca prepared in this embodiment was observed using transmission electron microscopy, and the results are as follows: Figure 9 As shown, its morphology is uniform, and it is covered with a Ca coating, with no visible pore structure.
[0034] Examples 3, 4, and 5 demonstrate that using antioxidant mesoporous silica spheres with a content of 0.9 g / mLTK-Si2 as a tool for screening Ca... 2+Layer concentration was investigated by adding different concentrations of CaCl2 solution to PMOs for self-assembly. Transmission electron microscopy was used to observe the morphological changes of the silicon spheres and the thickness of the Ca layer after self-assembly. Increasing the CaCl2 solution concentration resulted in a thicker layer, poorer silicon sphere dispersion, and hindered the antioxidant capacity of the self-assembled structure. The self-assembly state reached its optimal level when the CaCl2 solution concentration was 1 M.
[0035] Example 6 Rat models of respiratory arrest (RA) were established in 6-8 week old female Wistar rats using bovine type II collagen and incomplete Freund's adjuvant. Prior to modeling, orbital blood was collected from normal rats for a hemolysis test. The hemolysis test is primarily used to evaluate the biosafety of nanomedicines. Figure 16 As shown, when the corresponding curcumin concentration increased from 0.1875 mg / mL to 3 mg / mL, the hemolysis rate of erythrocytes was less than 4%, indicating that the materials all have good biocompatibility and can be used for tail vein injection. Rats with successfully established RA models were randomly divided into five groups of six each: Control group, PBS group, Curcumin group, PMOs group, and PMOs@Cur@Ca group. The Control group consisted of normal healthy rats, who were not subjected to modeling, drug administration, or injection of any solvent / drug; they were simply fed and sampled synchronously, serving as a blank normal control. Drug administration began on day 22 of modeling, with concentrations of Curcumin: 15 mg / kg, PMOs: 20 mg / kg, and PMOs@Cur@Ca: 35 mg / kg. The PBS group received the corresponding volume of PBS. All administration was via tail vein injection, every other day, for a total of 12 administrations. Photos were taken on days 9, 13, 17, 21, 25, 29, 33, 37, 41, and 45 to observe the degree of swelling in the paws. Figure 14 As shown, all groups showed some improvement after treatment, but the PMOs@Cur@Ca group showed the most significant reduction in swelling, the fastest onset of action, and the overall appearance most closely resembled the normal control group. The severity of joint inflammation was evaluated using an arthritis index score, with the following criteria: 0 points: no evidence of erythema and swelling; 1 point: erythema and mild swelling limited to the midfoot or ankle joint; 2 points: erythema and mild swelling spreading from the ankle joint to the midfoot; 3 points: erythema and mild swelling spreading from the ankle joint to the joint; 4 points: erythema and severe swelling including the ankle, foot, and toes. Each paw was scored separately according to the severity of the lesions and whether there was inflammation between the toes, recorded as 0-4 points. The cumulative score was the arthritis index for each rat. Figure 15As shown, the results demonstrated a significant decrease in the joint inflammation index of treated rats, with the PMOs@Cur@Ca group showing the most significant decrease. The anti-inflammatory effect was significantly better than that of the single Curcumin group and the PMOs group, indicating that the compound preparation could more effectively alleviate joint inflammation. After the final treatment, CIA rats were euthanized with CO2, perfused and fixed with PBS and 4% paraformaldehyde, and the heart, liver, spleen, lungs, and kidneys were removed and fixed with 4% paraformaldehyde for 21 days. Most of the muscles attached to the ankle joint were removed to obtain the left hind ankle joint of the rats. After fixation with 4% paraformaldehyde for 7 days, the ankle joint was decalcified with 10% EDTA for 20 days. Then, the heart, liver, spleen, lungs, kidneys, and ankle joint were cut into pieces and embedded in paraffin blocks. The pieces were sliced to 5 μm and mounted for hematoxylin-eosin (H&E) staining. Pathological changes in the heart, liver, spleen, lungs, kidneys, and ankle joints of CIA rats were observed. The biosafety of the drug was assessed by performing H&E staining and histological analysis on important organs (heart, liver, spleen, lung, and kidney) of CIA rats after treatment in each group. Figure 17 As shown, the PMOs@Cur@Ca group had intact cardiomyocyte morphology, less lysis and necrosis, clear liver lobule structure, mild hepatocyte damage, and spleen, lung, and kidney tissue structures that were close to normal. The overall tissue toxicity was lower than that of the Curcumin group and the PMOs group.
[0036] Comprehensive observation, arthritis index scores, and organ pathology results indicate that single free curcumin or blank PMOs carriers can only alleviate RA-related symptoms to a limited extent. In contrast, PMOs@Cur@Ca composite nanomaterials achieve stronger anti-inflammatory efficacy while possessing superior in vivo biocompatibility and lower systemic toxicity, making them a feasible treatment option for RA.
Claims
1. A method for preparing antioxidant mesoporous organosilicon self-assembled nanomaterials, characterized in that, Includes the following steps: S1. Preparation of TK-NH2; S1-1. Weigh mercaptoethylamine hydrochloride and add it to the reaction flask, then add concentrated hydrochloric acid and stir at room temperature until the solid is completely dissolved to obtain solution A with a concentration of 1.3~1.5 g / mL; S1-2. Prepare solution B by mixing acetone and dichloromethane at a volume ratio of (2-4):
1. S1-3. Transfer the solution A prepared in step S1-1 to a low-temperature water bath. While stirring, add the solution B prepared in step S1-2 to solution A. A white solid substance will appear in the reaction flask. Continue the reaction under low-temperature conditions in the water bath for 2-4 hours. The volume ratio between solution A and solution B is 1:(3-4). After the reaction in S1-4 is completed, methanol is added to the reaction solution in S1-3. Then, the product is recrystallized with dichloromethane and filtered. The solid substance is then dissolved in methanol. When the product is just dissolved, anhydrous diethyl ether is gradually added until no more white precipitate is formed. S1-5. The reaction product obtained in step S1-4 is filtered and then dissolved in NaOH solution and stirred at room temperature. The solution after reaction is extracted with dichloromethane, anhydrous sodium sulfate is added and stirred, and then anhydrous sodium sulfate is removed by filtration. The liquid obtained by filtration is evaporated to dryness to obtain the target product. The target product is then transferred to a sample bottle and dried overnight by an oil pump to obtain liquid ROS scavenging small molecule precursor TK-NH2. S2. Preparation of antioxidant mesoporous organosilicon spheres, abbreviated as PMOs; S2-1. Prepare an anhydrous and oxygen-free reaction flask. At room temperature, disperse the TK-NH2 and triethylamine prepared in step S1 in a reaction flask containing tetrahydrofuran. The volume ratio of TK-NH2, triethylamine and tetrahydrofuran is 1:(5-6):(50-60). S2-2, 3-isocyanopropyltrimethoxysilane is added dropwise to tetrahydrofuran and mixed to obtain solution C. The volume ratio of 3-isocyanopropyltrimethoxysilane to tetrahydrofuran is 1:(1-1.5). Solution C is added to the reaction flask in step S2-1 and reacted at room temperature for 10-16 h. After evaporation, the intermediate product TK-Si2 is obtained. S2-3. Disperse triethanolamine and hexadecyl p-toluenesulfonate in water and reflux with stirring to obtain solution D; in solution D, the concentrations of triethanolamine and hexadecyl p-toluenesulfonate are 2.7~3.2 g / L and 19~20 g / L, respectively; S2-4. Mix the intermediate product TK-Si2 obtained in step S2-2 with TEOS to obtain solution E; the concentration of intermediate product TK-Si2 in solution E is 0.8~8.2 g / mL; and add solution E dropwise to solution D obtained in step S2-3 while stirring; the volume ratio between solution E and solution D is 1:(9-38). S2-5. The product obtained in step S2-4 is centrifuged and washed, dispersed in HCl-methanol solution and refluxed, and then centrifuged and washed with anhydrous ethanol to obtain PMOs, which are then stored in anhydrous ethanol. S3. Preparation of antioxidant mesoporous organosilicon self-assembled nanomaterials, abbreviated as PMOs@Cur@Ca; S3-1. Take the anhydrous ethanol solution containing PMOs prepared in step S2, centrifuge and discard the supernatant, add curcumin-ethanol solution, the concentration of PMOs in the curcumin-ethanol solution is 5-5.5 g / L; sonicate. S3-2. Then, add 1-4M CaCl2 solution to the solution obtained in step S3-1, sonicate, and incubate overnight in a shaker at 100-120 rpm and 36-37℃; the volume ratio between CaCl2 solution and curcumin-ethanol solution is (10-11):1; centrifuge and discard the supernatant, wash with ethanol solution and freeze dry to obtain PMOs@Cur@Ca nanomaterials.
2. The method for preparing an antioxidant mesoporous organosilicon self-assembled nanomaterial according to claim 1, characterized in that, In step S2-2, the volume of solution C is 15-20% of the reaction solution in the reaction flask in step S2-1; in step S2-3, the reflux temperature is 80-90℃ and the stirring time is 1-1.5h.
3. A method for preparing an antioxidant mesoporous organosilicon self-assembled nanomaterial according to claim 1 or 2, characterized in that, In step S2-4, the stirring temperature is 80-90℃, the stirring speed is 800-1200r, and the stirring time is 12-16h; in step S2-5, the concentration of the HCl-methanol solution is 1.5-2M; the reflux temperature is 75-80℃, and the reflux time is 12-16h.
4. A method for preparing an antioxidant mesoporous organosilicon self-assembled nanomaterial according to claim 1 or 2, characterized in that, In step S3-1, the concentration of curcumin-ethanol solution is 3.8-4.0 mg / mL; sonicate for 10-20 min.
5. A method for preparing an antioxidant mesoporous organosilicon self-assembled nanomaterial according to claim 1 or 2, characterized in that, In step S3-2, sonication is performed for 15-20 minutes; the centrifugation parameters are: centrifugal force of 15000-17000g, centrifugation time of 3-5 minutes; and the concentration of the ethanol solution is 10-11%.
6. A method for preparing an antioxidant mesoporous organosilicon self-assembled nanomaterial according to claim 1 or 2, characterized in that, In steps S1-3, solution B is added to solution A at a dropping rate of 10-15 mL / min; the water bath temperature is -5℃ to 5℃; in steps S1-4, the volume ratio between methanol and dichloromethane is 1:(1-2).
7. A method for preparing an antioxidant mesoporous organosilicon self-assembled nanomaterial according to claim 1 or 2, characterized in that, In steps S1-5, the mass fraction of the NaOH solution is 22-27%; stirring at room temperature for 4-6 hours; extraction with dichloromethane 3-6 times; and stirring with anhydrous sodium sulfate for 10-12 minutes.
8. The antioxidant mesoporous organosilicon self-assembled nanomaterial prepared by the preparation method according to any one of claims 1-7, wherein the core of the material is a mesoporous organosilicon sphere and the outer coating is a spherical structure; the coating contains Ca. 2+ And curcumin.
9. The application of the antioxidant mesoporous organosilicon self-assembled nanomaterial as described in claim 8 in the preparation of a drug for treating inflammatory bone diseases.
10. The application of the antioxidant mesoporous organosilicon self-assembled nanomaterial as described in claim 9 in the preparation of a drug for treating inflammatory bone diseases, characterized in that, The inflammatory bone disease mentioned is rheumatoid arthritis.
